Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

VCT220

Stage Phase 3Stale

Sponsor Vincentage Pharma Co

Route oral

Class Oral small molecule

Mechanism small-molecule GLP-1 receptor agonist

Sources

registry, as of 2026-09-16Stale

https://clinicaltrials.gov/study/NCT06939296

A Research Study of VCT220 in Adult Chinese Participants With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 840. Conditions Obesity; Overweight. The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once da

ClinicalTrials.gov NCT06939296 protocol and results modules

registry, as of 2025-07-01Stale

https://clinicaltrials.gov/study/NCT06569355

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population. Overall status COMPLETED. Phases PHASE2. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 250. Conditions Obesity; Overweight. The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo

ClinicalTrials.gov NCT06569355 protocol and results modules

registry, as of 2026-09-21Stale

https://clinicaltrials.gov/study/NCT07360275

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 160. Conditions Hypertension. The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.

ClinicalTrials.gov NCT07360275 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07349381

A Food-Effect Study of CX11 in Healthy Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 32. Conditions Obesity & Overweight; Type 2 Diabetes. This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants

ClinicalTrials.gov NCT07349381 protocol and results modules

registry, as of 2026-03-31Stale

https://clinicaltrials.gov/study/NCT07056842

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole. Overall status COMPLETED. Phases PHASE1. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 32. Conditions Obesity &Amp; Overweight. This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite VCT289. Cohort 1 will assess the impact of rifampin

ClinicalTrials.gov NCT07056842 protocol and results modules

registry, as of 2026-03-31Stale

https://clinicaltrials.gov/study/NCT07065058

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Vincentage Pharma Co., Ltd. Enrollment 24. Conditions Obesity &Amp; Overweight. This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the pharmacokinetics and safety of repaglinide , rosuvastatin, and di

ClinicalTrials.gov NCT07065058 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06939296

Each participant will take the study drug orally once daily for 12 months. VCT220 A small molecule GLP-1R drug, film coated tablet Placebo Placebo tablets

NCT06939296 description or intervention text

Studies

A Research Study of VCT220 in Adult Chinese Participants With Obesity

Registry NCT06939296

Phase Phase 3

Status Completed

Enrollment 840

Start 2024-12-24

Primary completion 2025-11-25

Study completion 2026-03-31

Catalyst Primary completion. 2025-11-25. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

High dose group

Regimen once daily

Weeks 8

Comparator placebo

Population Obesity; Overweight

Moderate dose group

Regimen once daily

Weeks 8

Comparator placebo

Population Obesity; Overweight

Placebo group

Regimen once daily

Weeks 8

Population Obesity; Overweight

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

Registry NCT06569355

Phase Phase 2

Status Completed

Enrollment 250

Start 2023-12-27

Primary completion 2024-07-13

Study completion 2024-08-01

80mg dose group

Dose 80mg

Regimen once daily

Weeks 3

Population Obesity; Overweight

120mg dose group

Dose 120mg

Regimen once daily

Weeks 3

Population Obesity; Overweight

160mg dose group fast titration

Dose 160mg

Regimen once daily

Weeks 3

Population Obesity; Overweight

160mg dose group slow titration

Dose 160mg

Regimen once daily

Weeks 3

Population Obesity; Overweight

VICTOR-HTN

Registry NCT07360275

Phase Phase 2

Status Active, not recruiting

Enrollment 160

Start 2026-03-01

Primary completion 2026-10-30

Study completion 2026-12-20

Catalyst Primary completion. 2026-10-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

VCT220 80mg

Dose 80mg

Comparator placebo

Population Hypertension

Placebo

Population Hypertension

VCT220 160mg (1)

Dose 160mg

Comparator placebo

Population Hypertension

VCT220 160mg (2)

Dose 160mg

Comparator placebo

Population Hypertension

A Food-Effect Study of CX11 in Healthy Participants

Registry NCT07349381

Phase Phase 1

Status Completed

Enrollment 32

Start 2026-03-04

Primary completion 2026-06-30

Study completion 2026-08-30

Catalyst Primary completion. 2026-06-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Fasted-Fed Arm

Population Obesity & Overweight; Type 2 Diabetes

Fed-Fasted Arm

Population Obesity & Overweight; Type 2 Diabetes

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole

Registry NCT07056842

Phase Phase 1

Status Completed

Enrollment 32

Start 2025-07-20

Primary completion 2025-08-11

Study completion 2025-09-30

Catalyst Primary completion. 2025-08-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Experimental Arm

Regimen once daily

Population Obesity &Amp; Overweight

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

Registry NCT07065058

Phase Phase 1

Status Completed

Enrollment 24

Start 2025-07-01

Primary completion 2025-07-11

Study completion 2025-08-11

Catalyst Primary completion. 2025-07-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Participant Group

Regimen once daily

Population Obesity &Amp; Overweight